Long-term use of mepolizumab in a case of chronic eosinophilic pneumonia: extending interval dosing

Abstract

Introduction

Mepolizumab, a humanized anti IL-5 monoclonal antibody, has been used off-label for chronic eosinophilic pneumonia (CEP), inducing disease remission and saving systemic corticosteroids.

Case Study

We present a case of CEP, requiring long-term corticosteroids therapy due to relapse upon withdrawal. Mepolizumab was started and maintained for 2 years and 6 months.

Results

Corticosteroids could be withdrawn and mepolizumab dose interval was spared up to 10 wk with no disease relapse.

Conclusion

Mepolizumab is shown to be useful for chronic eosinophilic pneumonia, allowing corticosteroid withdrawal. Dose interval may be individualized under close monitoring, for a more efficient treatment, reducing medical costs while improving patients’ quality of life.

Keywords:

• Anti-IL5
• chronic eosinophilic pneumonia
• mepolizumab
• interval dosing
• steroids sparing

Declaration of interest

No potential conflict of interest was reported by the author(s).

Additional information

Funding

No financial support was provided for this study.